Challenges of conducting a trial of uric-acid-lowering therapy in CKD. (Q44235739)

1 December 2017

1 reference

title

Challenges of conducting a trial of uric-acid-lowering therapy in CKD. (English)

1 reference

1 December 2017

4

1 reference

1 December 2017

Vlado Perkovic

7

0 references

Sunil Badve

object named as

Sunil V Badve

1

0 references

Carmel Hawley

object named as

Carmel M Hawley

3

0 references

author name string

Fiona Brown

2

1 reference

1 December 2017

John Kanellis

5

1 reference

1 December 2017

Gopala K Rangan

6

1 reference

1 December 2017

language of work or name

English

0 references

publication date

15 February 2011

1 reference

Nature Reviews Nephrology

1 December 2017

1 reference

1 December 2017

7

1 reference

1 December 2017

295-300

1 reference

1 December 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2010.186

1 December 2017

0 references

cites work

Prevalence of chronic kidney disease in the United States

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Prevalence of kidney damage in Australian adults: The AusDiab kidney study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Change in estimated GFR associates with coronary heart disease and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Uric acid reduction: a new paradigm in the management of cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Risk factors for end-stage renal disease: 25-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Elevated uric acid increases the risk for kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Uric acid and incident kidney disease in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Relationship of uric acid with progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Uric acid correlates with the severity of histopathological parameters in IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Serum uric acid and endothelial dysfunction in continuous ambulatory peritoneal dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Uric acid and long-term outcomes in CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

J-shaped mortality relationship for uric acid in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Low serum uric acid level is a risk factor for death in incident hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

The independent association between serum uric acid and graft outcomes after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Hyperuricemia, gout, and renal function after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Uric acid and cardiovascular risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

Effect of Febuxostat on the Progression of Renal Disease in 5/6 Nephrectomy Rats with and without Hyperuricemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.186

The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21321568

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEPH.2010.186

1 reference

Dimensions Publication ID

1 December 2017

0 references

1 reference